Dr. Matthew Douglas Saybolt, MD

Dr. Saybolt practices at Monmouth Cardiology Associates in Eatontown, New Jersey.

Dr. Saybolt's NPI, 1841519709, was assigned on May 18, 2010. Dr. Saybolt graduated from Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) in 2010. Dr. Saybolt holds New Jersey license 25MA10222300.

Dr. Saybolt's primary practice is Monmouth Cardiology Associates, at 11 Meridian Rd, Eatontown, NJ 07724 in Monmouth County. The practice phone is (732) 663-0300.

Dr. Saybolt's primary practice is Monmouth Cardiology Associates in Eatontown, New Jersey. Dr. Saybolt is also affiliated with Jersey Shore University Medical Center. The medical group on file is Monmouth Cardiology Associates. Dmand AI also links Dr. Saybolt to 4 more hospitals, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saybolt practices, 8 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Saybolt's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dmand AI has Dr. Saybolt's licenses on file in 2 states: New Jersey and Pennsylvania.

CMS data shows 4,624 Medicare services from Dr. Saybolt across 31 procedure codes in 2024, for 1,348 Medicare patients. Medicare paid $510,147 for them.

CMS counts 1,348 Medicare patients who saw Dr. Saybolt in 2024. The largest group is 75 to 84, with 586 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saybolt's median patient age at 73, with 42% women.

In 2024, Dr. Saybolt wrote 4,772 Medicare Part D claims for 672 patients. 80% of them were for generic drugs. CMS names the drug for 4,437 of them, across 54 drugs with 11 or more claims each, at $1,285,886 in total drug cost. In 2023, CMS named 4,011 claims across 54 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Saybolt for performance year 2024, reported as part of a group. Dr. Saybolt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 61 procedures of coronary angioplasty and stenting by Dr. Saybolt, more than 89% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Saybolt, published from 2012 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement and Aortic Valve. Dr. Saybolt has published most often in Cardiovasc Revasc Med. Dr. Saybolt's most frequent co-authors are Daniel Harris Kiss, MD, Brett Andrew Sealove, MD and Paul Nicolas Fiorilli, MD.

Dmand AI links Dr. Saybolt to 2 clinical trials. 1 is still active or recruiting.

CMS Open Payments shows 940 general payments to Dr. Saybolt from 46 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Abbott Laboratories paid the most, $70,002.

Dr. Saybolt graduated from Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) in 2010.